Outcomes after definitive treatment for head and neck angiosarcoma.
angiosarcoma
rare cancer
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
08
03
2022
received:
30
01
2022
accepted:
22
03
2022
pubmed:
10
5
2022
medline:
15
6
2022
entrez:
9
5
2022
Statut:
ppublish
Résumé
Head and neck angiosarcoma (HN-AS) is a rare and aggressive, representing <1% of all head and neck malignancies. It is characterized by a high rate of local recurrence and poor 5-year survival (10-54%). Australian data in this rare disease is lacking. We aim review the clinical outcomes of HN-AS from two high volume head and neck cancer units in Australia. Retrospective chart review. A total 26 patients were identified, consist of predominantly male patients (81%) with a mean age of 77 year old. Most of the HN-AS arises from the scalp (62%). The 5-year overall survival (OS) and disease free survival (DFS) were 41% and 15%, respectively. Patients treated with upfront surgery with adjuvant therapy has better OS and DFS compared with patients receiving upfront chemoradiotherapy (median OS 3.63 vs. 0.53 years, P = 0.011 and median DFS 1.19 vs. 0.33 years, P = 0.001). There is no difference in OS or DFS for the sites of HN-AS or age of patients. Recurrences were noted in 15 patients (57.7%). For those with metastatic disease, the most common site was the lung (80%) with a median time to development of distant disease of 2.7 years (range 1.8-3.6 years). In patients who underwent salvage treatment, the median survival (post-salvage) was 1.3 years (0-2.8 years). This is the first Australian report of treatment patterns and outcomes of patients with HN-AS. Our cohort confirms that HN-AS is a slowly progressive disease with poor survival. Patients treated with surgery and adjuvant radiotherapy in this series had better outcomes compared with those treated with chemoradiotherapy alone. The role of neoadjuvant chemotherapy is an area of ongoing research.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1407-1414Informations de copyright
© 2022 Royal Australasian College of Surgeons.
Références
Hodgkinson DJ, Soule EH, Woods JE. Cutaneous angiosarcoma of the head and neck. Cancer 1979; 44: 1106-13.
Yang JC, Rosenberg SA, Glatstein EJ, Antman KH. Sarcomas of soft tissue. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, 4th edn. Philadelphia: J.B. Lippincott, 1993; 143.
Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 1987; 59: 1046-57.
Mendenhall WM, Mendenhall CM, Werning JW, Reith JD, Mendenhall NP. Cutaneous angiosarcoma. Am J Clin Oncol Cancer Clin Trials. 2006; 29: 524-8.
Pawlik TM, Paulino AF, McGinn CJ et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003; 98: 1716-26.
Michael BM, Michael S, Stephen S, William BS. Cutaneous angiosarcoma: a case series with prognostic correlation. J. Am. Acad. Dermatol. 2004; 50: 867-74.
Sasaki R, Soejima T, Kishi K et al. Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome. Int. J. Radiat. Oncol. Biol. Phys. 2002; 52: 1032-40.
Köhler HF, Neves RI, Brechtbühl ER, Mattos Granja NV, Ikeda MK, Kowalski LP. Cutaneous angiosarcoma of the head and neck: report of 23 cases from a single institution. Otolaryngol. Head Neck Surg. 2008; 139: 519-24.
Dettenborn T, Wermker K, Schulze HJ, Klein M, Schwipper V, Hallermann C. Prognostic features in angiosarcoma of the head and neck: a retrospective monocenter study. J. Craniomaxillofac. Surg. 2014; 42(8): 1623-8.
Italiano A, Cioffi A, Penel N et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 2012; 118: 3330-6.
Kimberley MH, IJzerman NS, van der Graaf WTA, Kerst JM et al. Neoadjuvant systemic therapy of primary angiosarcoma. Cancer 2020; 12: 2251.
https://clinicaltrials.gov/ct2/show/NCT03921008
Tamara T, Angela V, Melanie W, Suzanne D. Implementation of the SunSmart program and population sun protection behaviour in Melbourne, Australia: results from cross-sectional summer surveys from 1987 to 2017. PLoS Med. 2019; 16(10): e1002932.
Mark RJ, Tran LM, Sercarz J, Fu YS, Calcaterra TC, Juillard GF. Angiosarcoma of the head and neck. The UCLA experience 1955 through 1990. Arch. Otolaryngol. Head Neck Surg. 1993; 119: 973-97.
Perez MC, Padhya TA, Messina JL et al. Cutaneous angiosarcoma: a single-institution experience Matthew. Ann. Surg. Oncol. 2013; 20: 3391-7.
Ogawa K, Takahashi K, Asato Y et al. Treatment and prognosis of angiosarcoma of the scalp and face: a retrospective analysis of 48 patients. Br. J. Radiol. 2012; 85: 1127-33.
Fury MG, Antonescu CR, Van Zee K, Brennan ME, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005; 11: 241-7.
W. M. Lydiatt, A. R. Shaha, and J. P. Shah, “Angiosarcoma of the head and neck,” Am. J. Surg. 1994;168:451-454.
Guadagnolo BA, Zagars GK, Araujo D, Ravi V, Shellenberger TD, Sturgis EM. Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp b. Head Neck 2011; 33: 661-7.
Fujisawa Y, Yoshino K, Kadono T, Miyagawa T, Nakamura Y, Fujimoto M. Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study. Br. J. Dermatol. 2014; 154: 375-6.
Wollina U, Fuller J, Graefe T, Kaatz M, Lopatta E. Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy. J. Cancer Res. Clin. Oncol. 2001; 127: 396-9.
Naka N, Ohsawa M, Tomita Y, Kanno H, Aozasa K, Uchida A. Angiosarcoma in Japan. A review of 99 cases. Cancer 1995; 75: 989-96.
Olsen KD, Bradly Meland N, Aust MR et al. Angiosarcomas of the head and neck: clinical and pathologic characteristics. Ann. Otol. Rhinol. Laryngol. 1997; 106: 943-51.
Kuan CH, Yang HW, Huang HF et al. Prognostic significance of positive surgical margins for scalp angiosarcoma. J. Formos. Med. Assoc. 2021; 120(1 Pt 1): 217-25.
Mueller S, Gauthier M, Ashford B et al. Mutational patterns in metastatic cutaneous squamous cell carcinoma. J. Investig. Dermatol. 2019; 139: 1449-1458.e1.
Deyrup AT, Tighiouart M, Montag AG, Weiss SW. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am. J. Surg. Pathol. 2008b; 32: 924-e927.
Barnabas O, Wang H, Gao XM. Role of estrogen in angiogenesis in cardiovascular diseases. J. Geriatr. Cardiol. 2013; 10: 377-82.
Yang P, Zhu Q, Jiang F. Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature. Chin. J. Cancer Res. 2013; 25: 358-61.
Fuller CK, Charlson JA, Dankle SK, Russell TJ. Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J. Am. Acad. Dermatol. 2010; 63: 83-4.
Kang Y, Bae J, Choi S et al. Regional lymph node metastasis of scalp angiosarcoma: a detailed clinical observation study of 40 cases. Ann. Surg. Oncol. 2020; 27: 3018-27.